{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T19:59:17Z","timestamp":1766087957778},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Triple-negative breast cancer (TNBC) is associated with high mortality due to the high expression of pro-inflammatory cytokines and lack of targeted therapies. N-acylethanolamine acid amidase (NAAA) is an N-terminal cysteine hydrolase that promotes inflammatory responses through the deactivation of Palmitoylethanolamide (PEA), an endogenous bioactive lipid mediator. Here, we examined NAAA expression in TNBC cells (MDA-MB-231 and MDA-MB-BrM2 cells) and the effects of NAAA inhibition on TNBC tumor growth, using a selective NAAA inhibitor AM11095 (IC<jats:sub>50<\/jats:sub>\u2009=\u200920\u00a0nM). TNBC cells expressed elevated levels of full-length and splice mRNAs naaa variants. TNBC cells also express the N-acyl ethanol amides and elevated levels of the two fatty acid cores arachidonic (AA) and docosahexaenoic (DHA). PEA or AM11095 inhibited the secretion of IL-6 and IL-8, reduced the activation of the NF-kB pathway, decreased the expression of VEGF and Placental growth factor (PLGF) in TNBCs, and inhibited tumor cell migration in vitro. Using cellular magnetic resonance imaging (MRI), body images of mice administered with human MDA-MB-BrM2 cells treated with AM11095 showed a significant decrease in tumor numbers with a lower volume of tumors and increased mice survival. Mice untreated or treated with vehicle control showed a high number of tumors with high volumes in multiple organs. Thus, NAAA inhibition may constitute a potential therapeutic approach in the management of TNBC-associated inflammation and tumor growth.<\/jats:p>","DOI":"10.1038\/s41598-022-26564-6","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T16:06:06Z","timestamp":1671811566000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Inhibition of triple negative breast cancer-associated inflammation and progression by N- acylethanolamine acid amide hydrolase (NAAA)"],"prefix":"10.1038","volume":"12","author":[{"given":"Othman","family":"Benchama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Malamas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kulkarni","family":"Praveen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth C.","family":"Ethier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark K.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandros","family":"Makriyannis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hava Karsenty","family":"Avraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,23]]},"reference":[{"key":"26564_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000455820","volume":"12","author":"M Hubalek","year":"2017","unstructured":"Hubalek, M., Czech, T. & Muller, H. Biological subtypes of triple-negative breast cancer. Breast Care (Basel) 12, 8\u201314. https:\/\/doi.org\/10.1159\/000455820 (2017).","journal-title":"Breast Care (Basel)"},{"key":"26564_CR2","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1634\/theoncologist.2017-0095","volume":"22","author":"C Yam","year":"2017","unstructured":"Yam, C., Mani, S. A. & Moulder, S. L. Targeting the molecular subtypes of triple negative breast cancer: Understanding the diversity to progress the field. Oncologist 22, 1086\u20131093. https:\/\/doi.org\/10.1634\/theoncologist.2017-0095 (2017).","journal-title":"Oncologist"},{"key":"26564_CR3","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000478087","volume":"12","author":"MA Locatelli","year":"2017","unstructured":"Locatelli, M. A., Curigliano, G. & Eniu, A. Extended adjuvant chemotherapy in triple-negative breast cancer. Breast Care (Basel) 12, 152\u2013158. https:\/\/doi.org\/10.1159\/000478087 (2017).","journal-title":"Breast Care (Basel)"},{"key":"26564_CR4","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrc1388","volume":"4","author":"F Balkwill","year":"2004","unstructured":"Balkwill, F. Cancer and the chemokine network. Nat Rev Cancer 4, 540\u2013550. https:\/\/doi.org\/10.1038\/nrc1388 (2004).","journal-title":"Nat Rev Cancer"},{"key":"26564_CR5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ccr.2005.02.013","volume":"7","author":"F Balkwill","year":"2005","unstructured":"Balkwill, F., Charles, K. A. & Mantovani, A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7, 211\u2013217. https:\/\/doi.org\/10.1016\/j.ccr.2005.02.013 (2005).","journal-title":"Cancer Cell"},{"key":"26564_CR6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/1758834014521111","volume":"6","author":"S Crawford","year":"2014","unstructured":"Crawford, S. Anti-inflammatory\/antioxidant use in long-term maintenance cancer therapy: A new therapeutic approach to disease progression and recurrence. Ther. Adv. Med. Oncol. 6, 52\u201368. https:\/\/doi.org\/10.1177\/1758834014521111 (2014).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"26564_CR7","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/carcin\/bgp127","volume":"30","author":"F Colotta","year":"2009","unstructured":"Colotta, F., Allavena, P., Sica, A., Garlanda, C. & Mantovani, A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30, 1073\u20131081. https:\/\/doi.org\/10.1093\/carcin\/bgp127 (2009).","journal-title":"Carcinogenesis"},{"key":"26564_CR8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1158\/1541-7786.MCR-05-0261","volume":"4","author":"H Lu","year":"2006","unstructured":"Lu, H., Ouyang, W. & Huang, C. Inflammation, a key event in cancer development. Mol. Cancer Res. 4, 221\u2013233. https:\/\/doi.org\/10.1158\/1541-7786.MCR-05-0261 (2006).","journal-title":"Mol. Cancer Res."},{"key":"26564_CR9","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1179\/135100002125001135","volume":"7","author":"F Okada","year":"2002","unstructured":"Okada, F. Inflammation and free radicals in tumor development and progression. Redox Rep. 7, 357\u2013368. https:\/\/doi.org\/10.1179\/135100002125001135 (2002).","journal-title":"Redox Rep."},{"key":"26564_CR10","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1038\/s41467-018-05800-6","volume":"9","author":"G Schett","year":"2018","unstructured":"Schett, G. & Neurath, M. F. Resolution of chronic inflammatory disease: universal and tissue-specific concepts. Nat. Commun. 9, 3261. https:\/\/doi.org\/10.1038\/s41467-018-05800-6 (2018).","journal-title":"Nat. Commun."},{"key":"26564_CR11","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.ejca.2006.01.013","volume":"42","author":"L Yan","year":"2006","unstructured":"Yan, L., Anderson, G. M., DeWitte, M. & Nakada, M. T. Therapeutic potential of cytokine and chemokine antagonists in cancer therapy. Eur. J. Cancer 42, 793\u2013802. https:\/\/doi.org\/10.1016\/j.ejca.2006.01.013 (2006).","journal-title":"Eur. J. Cancer"},{"key":"26564_CR12","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/149185","volume":"2014","author":"G Landskron","year":"2014","unstructured":"Landskron, G., De la Fuente, M., Thuwajit, P., Thuwajit, C. & Hermoso, M. A. Chronic inflammation, and cytokines in the tumor microenvironment. J. Immunol. Res. 2014, 149185. https:\/\/doi.org\/10.1155\/2014\/149185 (2014).","journal-title":"J. Immunol. Res."},{"key":"26564_CR13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3389\/fphar.2013.00068","volume":"4","author":"S Crawford","year":"2013","unstructured":"Crawford, S. Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy. Front. Pharmacol. 4, 68. https:\/\/doi.org\/10.3389\/fphar.2013.00068 (2013).","journal-title":"Front. Pharmacol."},{"key":"26564_CR14","doi-asserted-by":"publisher","first-page":"7053","DOI":"10.7150\/thno.41388","volume":"10","author":"H Li","year":"2020","unstructured":"Li, H., Feng, Z. & He, M. L. Lipid metabolism alteration contributes to and maintains the properties of cancer stem cells. Theranostics 10, 7053\u20137069. https:\/\/doi.org\/10.7150\/thno.41388 (2020).","journal-title":"Theranostics"},{"key":"26564_CR15","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/ncb3124","volume":"17","author":"LK Boroughs","year":"2015","unstructured":"Boroughs, L. K. & DeBerardinis, R. J. Metabolic pathways promoting cancer cell survival and growth. Nat. Cell Biol. 17, 351\u2013359. https:\/\/doi.org\/10.1038\/ncb3124 (2015).","journal-title":"Nat. Cell Biol."},{"key":"26564_CR16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00018-015-2070-4","volume":"73","author":"Z Li","year":"2016","unstructured":"Li, Z. & Zhang, H. Reprogramming of glucose, fatty acid, and amino acid metabolism for cancer progression. Cell Mol. Life Sci. 73, 377\u2013392. https:\/\/doi.org\/10.1007\/s00018-015-2070-4 (2016).","journal-title":"Cell Mol. Life Sci."},{"key":"26564_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/metabo10090345","author":"C Ferreri","year":"2020","unstructured":"Ferreri, C., Sansone, A., Ferreri, R., Amezaga, J. & Tueros, I. Fatty acids and membrane lipidomics in oncology: A crossroad of nutritional. Signal. Metab. Pathways. Metab. https:\/\/doi.org\/10.3390\/metabo10090345 (2020).","journal-title":"Signal. Metab. Pathways. Metab."},{"key":"26564_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.critrevonc.2015.10.011","volume":"97","author":"U Harjes","year":"2016","unstructured":"Harjes, U., Kalucka, J. & Carmeliet, P. Targeting fatty acid metabolism in cancer and endothelial cells. Crit. Rev. Oncol. Hematol. 97, 15\u201321. https:\/\/doi.org\/10.1016\/j.critrevonc.2015.10.011 (2016).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"26564_CR19","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/j.bbalip.2013.07.008","volume":"1831","author":"SM Louie","year":"2013","unstructured":"Louie, S. M., Roberts, L. S., Mulvihill, M. M., Luo, K. & Nomura, D. K. Cancer cells incorporate and remodel exogenous palmitate into structural and oncogenic signaling lipids. Biochim. Biophys. Acta 1831, 1566\u20131572. https:\/\/doi.org\/10.1016\/j.bbalip.2013.07.008 (2013).","journal-title":"Biochim. Biophys. Acta"},{"key":"26564_CR20","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/nn.3612","volume":"17","author":"D Piomelli","year":"2014","unstructured":"Piomelli, D. & Sasso, O. Peripheral gating of pain signals by endogenous lipid mediators. Nat. Neurosci. 17, 164\u2013174. https:\/\/doi.org\/10.1038\/nn.3612 (2014).","journal-title":"Nat. Neurosci."},{"key":"26564_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2015.49","volume":"5","author":"S Beloribi-Djefaflia","year":"2016","unstructured":"Beloribi-Djefaflia, S., Vasseur, S. & Guillaumond, F. Lipid metabolic reprogramming in cancer cells. Oncogenesis 5, e189. https:\/\/doi.org\/10.1038\/oncsis.2015.49 (2016).","journal-title":"Oncogenesis"},{"key":"26564_CR22","doi-asserted-by":"publisher","first-page":"916","DOI":"10.2174\/187152711799219307","volume":"10","author":"A Truini","year":"2011","unstructured":"Truini, A. et al. Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy. CNS Neurol. Disord. Drug Targets 10, 916\u2013920. https:\/\/doi.org\/10.2174\/187152711799219307 (2011).","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"26564_CR23","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/151028","volume":"2013","author":"JM Keppel Hesselink","year":"2013","unstructured":"Keppel Hesselink, J. M., de Boer, T. & Witkamp, R. F. Palmitoylethanolamide: A natural body-own anti-inflammatory agent, effective and safe against influenza and common cold. Int. J. Inflamm. 2013, 151028. https:\/\/doi.org\/10.1155\/2013\/151028 (2013).","journal-title":"Int. J. Inflamm."},{"key":"26564_CR24","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/328797","volume":"2013","author":"L Di Cesare Mannelli","year":"2013","unstructured":"Di Cesare Mannelli, L. et al. Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: Pain relief and neuroprotection share a PPAR-alpha-mediated mechanism. Mediators Inflamm. 2013, 328797. https:\/\/doi.org\/10.1155\/2013\/328797 (2013).","journal-title":"Mediators Inflamm."},{"key":"26564_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2174\/1871527311312010010","volume":"12","author":"E Esposito","year":"2013","unstructured":"Esposito, E. & Cuzzocrea, S. Palmitoylethanolamide in homeostatic and traumatic central nervous system injuries. CNS Neurol. Disord. Drug Targets 12, 55\u201361. https:\/\/doi.org\/10.2174\/1871527311312010010 (2013).","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"26564_CR26","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1093\/hmg\/ddv477","volume":"25","author":"MA Esmaeili","year":"2016","unstructured":"Esmaeili, M. A. et al. Preferential PPAR-alpha activation reduces neuroinflammation, and blocks neurodegeneration in vivo. Hum. Mol. Genet. 25, 317\u2013327. https:\/\/doi.org\/10.1093\/hmg\/ddv477 (2016).","journal-title":"Hum. Mol. Genet."},{"key":"26564_CR27","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1476-4598-12-86","volume":"12","author":"B Hoesel","year":"2013","unstructured":"Hoesel, B. & Schmid, J. A. The complexity of NF-kappaB signaling in inflammation and cancer. Mol. Cancer 12, 86. https:\/\/doi.org\/10.1186\/1476-4598-12-86 (2013).","journal-title":"Mol. Cancer"},{"key":"26564_CR28","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.3390\/cancers3022214","volume":"3","author":"HY Fang","year":"2011","unstructured":"Fang, H. Y. & Greten, F. R. Cell autonomous and non-autonomous functions of IKKbeta and NF-kappaB during the pathogenesis of gastrointestinal tumors. Cancers (Basel) 3, 2214\u20132222. https:\/\/doi.org\/10.3390\/cancers3022214 (2011).","journal-title":"Cancers (Basel)"},{"key":"26564_CR29","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.neuropharm.2018.11.013","volume":"144","author":"C Sagheddu","year":"2019","unstructured":"Sagheddu, C. et al. Inhibition of N-acylethanolamine acid amidase reduces nicotine-induced dopamine activation and reward. Neuropharmacology 144, 327\u2013336. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.11.013 (2019).","journal-title":"Neuropharmacology"},{"key":"26564_CR30","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1096\/fj.14-255208","volume":"29","author":"M Alhouayek","year":"2015","unstructured":"Alhouayek, M. et al. N-Acylethanolamine-hydrolyzing acid amidase inhibition increases colon N-palmitoylethanolamine levels and counteracts murine colitis. FASEB J. 29, 650\u2013661. https:\/\/doi.org\/10.1096\/fj.14-255208 (2015).","journal-title":"FASEB J."},{"key":"26564_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1124\/mol.104.006353","volume":"67","author":"J Lo Verme","year":"2005","unstructured":"Lo Verme, J. et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol. Pharmacol. 67, 15\u201319. https:\/\/doi.org\/10.1124\/mol.104.006353 (2005).","journal-title":"Mol. Pharmacol."},{"issue":"121","key":"26564_CR32","first-page":"2","volume":"2","author":"JM Hesselink","year":"2013","unstructured":"Hesselink, J. M. Palmitoylethanolamide: A useful adjunct in chemotherapy providing analgesia and neuroprotection. Chemother. Open Access 2(121), 2 (2013).","journal-title":"Chemother. Open Access"},{"key":"26564_CR33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2174\/1876386301205010012","volume":"5","author":"JM Keppel Hesselink","year":"2012","unstructured":"Keppel Hesselink, J. M. New targets in pain, non-neuronal cells, and the role of palmitoylethanolamide. Open Pain J. 5, 12\u201323 (2012).","journal-title":"Open Pain J."},{"key":"26564_CR34","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/path.4304","volume":"232","author":"HK Avraham","year":"2014","unstructured":"Avraham, H. K. et al. Angiopoietin-2 mediates blood-brain barrier impairment and colonization of triple-negative breast cancer cells in brain. J. Pathol. 232, 369\u2013381. https:\/\/doi.org\/10.1002\/path.4304 (2014).","journal-title":"J. Pathol."},{"key":"26564_CR35","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1016\/j.bbalip.2016.09.018","volume":"1861","author":"Y Sakura","year":"2016","unstructured":"Sakura, Y. et al. A quantitative study on splice variants of N-acylethanolamine acid amidase in human prostate cancer cells and other cells. Biochim. Biophys. Acta 1861, 1951\u20131958. https:\/\/doi.org\/10.1016\/j.bbalip.2016.09.018 (2016).","journal-title":"Biochim. Biophys. Acta"},{"key":"26564_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.729464","volume":"12","author":"J Qiao","year":"2021","unstructured":"Qiao, J. et al. Quantitative imaging of blood-brain barrier permeability following repetitive mild head impacts. Front. Neurol. 12, 729464. https:\/\/doi.org\/10.3389\/fneur.2021.729464 (2021).","journal-title":"Front. Neurol."},{"key":"26564_CR37","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.celrep.2014.08.049","volume":"9","author":"DJ Wang","year":"2014","unstructured":"Wang, D. J., Ratnam, N. M., Byrd, J. C. & Guttridge, D. C. NF-kappaB functions in tumor initiation by suppressing the surveillance of both innate and adaptive immune cells. Cell Rep. 9, 90\u2013103. https:\/\/doi.org\/10.1016\/j.celrep.2014.08.049 (2014).","journal-title":"Cell Rep."},{"key":"26564_CR38","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nature02924","volume":"431","author":"E Pikarsky","year":"2004","unstructured":"Pikarsky, E. et al. NF-kappaB functions as a tumor promoter in inflammation-associated cancer. Nature 431, 461\u2013466. https:\/\/doi.org\/10.1038\/nature02924 (2004).","journal-title":"Nature"},{"key":"26564_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines5030050","author":"F Begalli","year":"2017","unstructured":"Begalli, F. et al. Unlocking the NF-kappaB conundrum: Embracing complexity to achieve specificity. Biomedicines https:\/\/doi.org\/10.3390\/biomedicines5030050 (2017).","journal-title":"Biomedicines"},{"key":"26564_CR40","doi-asserted-by":"publisher","first-page":"628","DOI":"10.14348\/molcells.2019.0038","volume":"42","author":"C Ma","year":"2019","unstructured":"Ma, C. et al. Knockdown of pyruvate kinase M inhibits cell growth and migration by reducing NF-kB activity in triple-negative breast cancer cells. Mol. Cells 42, 628\u2013636. https:\/\/doi.org\/10.14348\/molcells.2019.0038 (2019).","journal-title":"Mol. Cells"},{"key":"26564_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-021-01116-4","author":"M Congiu","year":"2021","unstructured":"Congiu, M. et al. N-acylethanolamine acid amidase inhibition potentiates morphine analgesia and delays the development of tolerance. Neurotherapeutics https:\/\/doi.org\/10.1007\/s13311-021-01116-4 (2021).","journal-title":"Neurotherapeutics"},{"key":"26564_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.599995","volume":"11","author":"Y Tan","year":"2021","unstructured":"Tan, Y. et al. PPAR-alpha modulators as current and potential cancer treatments. Front. Oncol. 11, 599995. https:\/\/doi.org\/10.3389\/fonc.2021.599995 (2021).","journal-title":"Front. Oncol."},{"key":"26564_CR43","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","volume":"6","author":"H Zhao","year":"2021","unstructured":"Zhao, H. et al. Inflammation and tumor progression: Signaling pathways and targeted intervention. Sig. Transduct. Target Ther. 6, 263. https:\/\/doi.org\/10.1038\/s41392-021-00658-5 (2021).","journal-title":"Sig. Transduct. Target Ther."},{"key":"26564_CR44","doi-asserted-by":"publisher","first-page":"15584","DOI":"10.1038\/ncomms15584","volume":"8","author":"H Jayatilaka","year":"2017","unstructured":"Jayatilaka, H. et al. Synergistic IL-6 and IL-8 paracrine signaling pathway infers a strategy to inhibit tumor cell migration. Nat. Commun. 8, 15584. https:\/\/doi.org\/10.1038\/ncomms15584 (2017).","journal-title":"Nat. Commun."},{"key":"26564_CR45","doi-asserted-by":"publisher","first-page":"102766","DOI":"10.1016\/j.isci.2021.102766","volume":"24","author":"M Wang","year":"2021","unstructured":"Wang, M. et al. Programmed PPAR-alpha downregulation induces inflammation by suppressing fatty acid catabolism in monocytes. iScience 24, 102766. https:\/\/doi.org\/10.1016\/j.isci.2021.102766 (2021).","journal-title":"iScience"},{"key":"26564_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176054","author":"P Hankittichai","year":"2020","unstructured":"Hankittichai, P. et al. Oxyresveratrol inhibits IL-1beta-induced inflammation via suppressing AKT and ERK1\/2 activation in human microglia, HMC3. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms21176054 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"26564_CR47","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1124\/pr.119.018440","volume":"72","author":"U Bharadwaj","year":"2020","unstructured":"Bharadwaj, U., Kasembeli, M. M., Robinson, P. & Tweardy, D. J. Targeting janus kinases and signal transducer and activator of transcription 3 to treat inflammation, fibrosis, and cancer: rationale, progress, and caution. Pharmacol Rev 72, 486\u2013526. https:\/\/doi.org\/10.1124\/pr.119.018440 (2020).","journal-title":"Pharmacol Rev"},{"issue":"4","key":"26564_CR48","doi-asserted-by":"publisher","first-page":"E655","DOI":"10.1208\/aapsj080474","volume":"8","author":"J Williams","year":"2006","unstructured":"Williams, J., Pandarinathan, L., Wood, J., Vouros, P. & Makriyannis, A. Endocannabinoid metabolomics: A novel liquid chromatography-mass spectrometry reagent for fatty acid analysis. AAPS J. 8(4), E655\u2013E660. https:\/\/doi.org\/10.1208\/aapsj080474 (2006).","journal-title":"AAPS J."},{"issue":"5","key":"26564_CR49","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1021\/cn300007s","volume":"3","author":"T Tai","year":"2012","unstructured":"Tai, T. et al. Endogenous molecules stimulating N-acylethanolamine-hydrolyzing acid amidase (NAAA). ACS Chem. Neurosci. 3(5), 379\u2013385. https:\/\/doi.org\/10.1021\/cn300007s (2012).","journal-title":"ACS Chem. Neurosci."},{"key":"26564_CR50","doi-asserted-by":"publisher","first-page":"818","DOI":"10.3389\/fphar","volume":"10","author":"K Wu","year":"2019","unstructured":"Wu, K., Xiu, Y., Zhou, P., Qiu, Y. & Li, Y. A new use for an old drug: Carmofur attenuates lipopolysaccharide (LPS)-induced acute lung injury via inhibition of FAAH and NAAA Activities. Front. Pharmacol. 10, 818. https:\/\/doi.org\/10.3389\/fphar (2019).","journal-title":"Front. Pharmacol."},{"key":"26564_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105816","volume":"172","author":"S Sgroi","year":"2021","unstructured":"Sgroi, S. et al. Inhibition of N-acylethanolamine-hydrolyzing acid amidase reduces T cell infiltration in a mouse model of multiple sclerosis. Pharmacol. Res. 172, 105816. https:\/\/doi.org\/10.1016\/j.phrs.2021.105816 (2021).","journal-title":"Pharmacol. Res."},{"key":"26564_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104264","volume":"145","author":"P Zhou","year":"2019","unstructured":"Zhou, P. et al. N-Acylethanolamine acid amidase (NAAA) inhibitor F215 as a novel therapeutic agent for osteoarthritis. Pharmacol. Res. 145, 104264. https:\/\/doi.org\/10.1016\/j.phrs.2019.104264 (2019).","journal-title":"Pharmacol. Res."},{"issue":"1","key":"26564_CR53","doi-asserted-by":"publisher","first-page":"5328","DOI":"10.1038\/s41598-022-09358-8","volume":"12","author":"O Benchama","year":"2022","unstructured":"Benchama, O. et al. Inhibition of triple negative breast cancer-associated inflammation, tumor growth and brain colonization by targeting monoacylglycerol lipase. Sci. Rep. 12(1), 5328. https:\/\/doi.org\/10.1038\/s41598-022-09358-8 (2022).","journal-title":"Sci. Rep."},{"issue":"7837","key":"26564_CR54","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41586-020-2969-2","volume":"588","author":"X Jin","year":"2020","unstructured":"Jin, X. et al. A metastasis map of human cancer cell lines. Nature 588(7837), 331\u2013336. https:\/\/doi.org\/10.1038\/s41586-020-2969-2 (2020).","journal-title":"Nature"},{"key":"26564_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174561","volume":"912","author":"Y Li","year":"2021","unstructured":"Li, Y. et al. NAAA inhibitor F96 attenuates BBB disruption and secondary injury after traumatic brain injury (TBI). Eur. J. Pharmacol. 912, 174561. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174561 (2021).","journal-title":"Eur. J. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-26564-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-26564-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-26564-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T16:10:43Z","timestamp":1671811843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-26564-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,23]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["26564"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-26564-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,23]]},"assertion":[{"value":"17 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22255"}}